应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ZLAB 再鼎医药
休市中 04-26 16:00:00 EDT
15.91
+0.17
+1.08%
盘后
15.91
+0.00
0.00%
16:06 EDT
最高
16.05
最低
15.65
成交量
36.44万
今开
15.83
昨收
15.74
日振幅
2.54%
总市值
15.71亿
流通市值
14.12亿
总股本
9,872万
成交额
579.80万
换手率
0.41%
流通股本
8,878万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
再鼎医药:2024年第一季度业绩将于5月8日美国东部时间、5月9日香港时间发布
金融界港股 · 04-26 16:52
再鼎医药:2024年第一季度业绩将于5月8日美国东部时间、5月9日香港时间发布
再鼎医药下跌2.27%,报15.31美元/股
金融界 · 04-25 21:34
再鼎医药下跌2.27%,报15.31美元/股
再鼎医药涨超5% 原先声药业副总裁将加入公司任大中华区首席商务官
新浪财经 · 04-24
再鼎医药涨超5% 原先声药业副总裁将加入公司任大中华区首席商务官
再鼎医药上涨5.03%,报15.88美元/股
金融界 · 04-24
再鼎医药上涨5.03%,报15.88美元/股
再鼎医药:朱彤出任大中华区首席商务官
中国网财经 · 04-24
再鼎医药:朱彤出任大中华区首席商务官
总裁离职!再鼎医药发生高层换血,“2025年前实现盈利”目标能否实现?
金融界 · 04-23
总裁离职!再鼎医药发生高层换血,“2025年前实现盈利”目标能否实现?
再鼎医药盘中异动 股价大涨5.12%报14.79美元
自选股智能写手 · 04-22
再鼎医药盘中异动 股价大涨5.12%报14.79美元
新人 | 再鼎医药大中华区总裁离职
健识局 · 04-22
新人 | 再鼎医药大中华区总裁离职
再鼎医药首席商务官梁怡离职:朱彤接任大中华区新职位
和讯网 · 04-22
再鼎医药首席商务官梁怡离职:朱彤接任大中华区新职位
再鼎医药大中华区首席商务官梁怡月底离任,前先声再明首席运营官朱彤接任
界面 · 04-22
再鼎医药大中华区首席商务官梁怡月底离任,前先声再明首席运营官朱彤接任
南向资金4月18日净卖出再鼎医药75.56万股 连续3日减持
自选股智能写手 · 04-19
南向资金4月18日净卖出再鼎医药75.56万股 连续3日减持
再鼎医药(09688)股价下跌5.179%,现价港币$10.62
阿斯达克财经 · 04-18
再鼎医药(09688)股价下跌5.179%,现价港币$10.62
再鼎医药盘中异动 股价大跌5.03%
自选股智能写手 · 04-17
再鼎医药盘中异动 股价大跌5.03%
再鼎医药(09688)股价下跌5.026%,现价港币$10.96
阿斯达克财经 · 04-15
再鼎医药(09688)股价下跌5.026%,现价港币$10.96
再鼎医药下跌5.03%,报14.26美元/股
金融界 · 04-13
再鼎医药下跌5.03%,报14.26美元/股
再鼎医药盘中异动 股价大跌5.00%报14.26美元
自选股智能写手 · 04-13
再鼎医药盘中异动 股价大跌5.00%报14.26美元
再鼎医药下跌5.43%,报15.15美元/股
金融界 · 04-11
再鼎医药下跌5.43%,报15.15美元/股
再鼎医药盘中异动 股价大跌5.11%
自选股智能写手 · 04-11
再鼎医药盘中异动 股价大跌5.11%
美银证券降再鼎医药目标价至16.04元,评级“买入”
阿斯达克财经 · 04-10
美银证券降再鼎医药目标价至16.04元,评级“买入”
再鼎医药上涨2.03%,报15.76美元/股
金融界 · 04-05
再鼎医药上涨2.03%,报15.76美元/股
公司概况
公司名称:
再鼎医药
所属市场:
NASDAQ
上市日期:
--
主营业务:
Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。
发行价格:
--
{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":15.91,"timestamp":1714161600000,"preClose":15.74,"halted":0,"volume":364380,"hourTrading":{"tag":"盘后","latestPrice":15.91,"preClose":15.91,"latestTime":"16:06 EDT","volume":1928,"amount":30674.48,"timestamp":1714161989782},"delay":0,"floatShares":88780449,"shares":98717523,"eps":-3.462562,"marketStatus":"休市中","marketStatusCode":7,"change":0.17,"latestTime":"04-26 16:00:00 EDT","open":15.83,"high":16.05,"low":15.65,"amount":5798044.80354,"amplitude":0.025413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.462562,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714377600000},"adr":1,"listingDate":1505880000000,"adjPreClose":15.74,"adrRate":10,"postHourTrading":{"tag":"盘后","latestPrice":15.91,"preClose":15.91,"latestTime":"16:06 EDT","volume":1928,"amount":30674.48,"timestamp":1714161989782},"volumeRatio":0.7775321003666725},"requestUrl":"/m/hq/s/ZLAB/wiki","defaultTab":"wiki","newsList":[{"id":"2430723247","title":"再鼎医药:2024年第一季度业绩将于5月8日美国东部时间、5月9日香港时间发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2430723247","media":"金融界港股","top":-1,"share":"https://www.laohu8.com/m/news/2430723247?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:52","pubTimestamp":1714121573,"startTime":"0","endTime":"0","summary":"金融界4月26日消息,再鼎医药的董事会评审委员会将于2024年5月8日 /2024年5月9日审理并批准公司及其附属公司于2024年3月31日止的三个月未经审核季度业绩。再鼎医药的管理层计划在业绩公告发布后,于2024年5月9日上午8:00/2024年5月9日下午8:00,举行业绩电话会议和网络直播,讨论第一季度业绩并回答问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26165240431924.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430228549","title":"再鼎医药下跌2.27%,报15.31美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430228549","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430228549?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:34","pubTimestamp":1714052096,"startTime":"0","endTime":"0","summary":"4月25日,再鼎医药(ZLAB)开盘下跌2.27%,截至21:34,报15.31美元/股,成交30.57万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25213440414146.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429899450","title":"再鼎医药涨超5% 原先声药业副总裁将加入公司任大中华区首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2429899450","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2429899450?lang=zh_cn&edition=full","pubTime":"2024-04-24 23:02","pubTimestamp":1713970924,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)涨超5%,报15.88美元。4月22日消息,原先声药业副总裁朱彤加入再鼎医药担任大中华区首席商务官,现任首席商务官兼大中华区总裁梁怡将于4月30日离职。再鼎医药已向媒体确认了这一消息。资料显示,朱彤在医药营销领域经验丰富,曾在阿斯利康、罗氏、赛诺菲等知名跨国药企任职。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:郭明煜","market":"us","thumbnail":"http://n.sinaimg.cn/spider20240424/615/w350h265/20240424/eab8-5b47518ce2acab90a934a6d108dffb59.jpg","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/spider20240424/615/w350h265/20240424/eab8-5b47518ce2acab90a934a6d108dffb59.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-04-24/doc-inasxzhp0788846.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429456197","title":"再鼎医药上涨5.03%,报15.88美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429456197","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429456197?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:30","pubTimestamp":1713965432,"startTime":"0","endTime":"0","summary":"4月24日,再鼎医药(ZLAB)开盘上涨5.03%,截至21:30,报15.88美元/股,成交14.14万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24213040392882.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429548068","title":"再鼎医药:朱彤出任大中华区首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2429548068","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2429548068?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:36","pubTimestamp":1713951377,"startTime":"0","endTime":"0","summary":"中国网财经4月24日讯日前,中国网财经从再鼎医药处获悉,先声再明原首席运营官朱彤将加入公司,担任大中华区首席商务官。而公司原首席商务官兼大中华区总裁梁怡将于4月底离任。公开资料显示,在加入再鼎医药之前,朱彤曾在先声药业、阿斯利康中国、赛诺菲等知名企业任职,有丰富的跨国药企工作经验。再鼎医药作为创新药企,产品主要聚焦肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病等领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404243057722115.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404243057722115.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429135029","title":"总裁离职!再鼎医药发生高层换血,“2025年前实现盈利”目标能否实现?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429135029","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429135029?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:45","pubTimestamp":1713840333,"startTime":"0","endTime":"0","summary":"4月22日消息,原先声药业副总裁朱彤加入再鼎医药担任大中华区首席商务官,现任首席商务官兼大中华区总裁梁怡将于4月30日离职。再鼎医药已向媒体确认了这一消息。值得注意的是,作为中国创新药企的代表,再鼎医药此时正处于向“2025年前实现盈利”之目标全力加速的关键时刻,因而此时的高层变动格外引发市场关注。他在阿斯利康中国担任副总裁期间,负责心血管、肾脏及代谢事业部。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/23104540361213.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429868921","title":"再鼎医药盘中异动 股价大涨5.12%报14.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429868921","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429868921?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:31","pubTimestamp":1713792671,"startTime":"0","endTime":"0","summary":"北京时间2024年04月22日21时31分,再鼎医药股票出现波动,股价大幅上涨5.12%。截至发稿,该股报14.79美元/股,成交量7968股,换手率0.01%,振幅0.64%。再鼎医药股票所在的生物技术行业中,整体涨幅为0.57%。其相关个股中,Moolec Science Sa C/Wts 、Moolec Science Sa、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大,Moolec Science Sa、Adial Pharmaceuticals, Inc、亚狮康药业较为活跃,换手率分别为85.40%、44.25%、32.57%,振幅较大的相关个股有Moolec Science Sa C/Wts 、Moolec Science Sa、Nkgen Biotech, Inc.,振幅分别为86.63%、18.57%、11.75%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042221311279225572&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042221311279225572&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429410928","title":"新人 | 再鼎医药大中华区总裁离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2429410928","media":"健识局","top":-1,"share":"https://www.laohu8.com/m/news/2429410928?lang=zh_cn&edition=full","pubTime":"2024-04-22 20:09","pubTimestamp":1713787768,"startTime":"0","endTime":"0","summary":"一则“再鼎医药首席商务官兼大中华区总裁梁怡将于4月30日离职”的消息在业界广为流传。2018年6月,梁怡加盟再鼎医药,出任公司首席商务官、兼任大中华区总裁。任职期间,梁怡帮助再鼎医药搭建商业化团队,则乐、爱普盾、擎乐、纽再乐等一批产品获批上市。对于梁怡未来工作的去向,再鼎医药表示公司不知情。4月22日,前先声药业首席运营官、先声药业高级副总裁朱彤宣布加盟再鼎医药,担任大中华区首席商务官,接替梁怡的职位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404222026278b46208a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404222026278b46208a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429923096","title":"再鼎医药首席商务官梁怡离职:朱彤接任大中华区新职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2429923096","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429923096?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:20","pubTimestamp":1713781245,"startTime":"0","endTime":"0","summary":"快讯正文【再鼎医药商业化团队搭建者梁怡离任,朱彤接替首席商务官】再鼎医药宣布,前首席商务官兼大中华区总裁梁怡将于4月30日正式离职,其职责将由先声药业高级副总裁朱彤接替。朱彤的加入预示着再鼎医药在商业化道路上的全新布局。梁怡在任期间成功搭建了公司商业化团队,为再鼎医药的商业发展奠定基础。尽管再鼎医药未对此次人事变动提供详细理由,但梁怡的离任及朱彤的加入或将为公司带来新的商业策略与市场机遇。下载和讯APP查看快讯,体验更佳>>","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042220421087a170bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042220421087a170bf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429921199","title":"再鼎医药大中华区首席商务官梁怡月底离任,前先声再明首席运营官朱彤接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2429921199","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2429921199?lang=zh_cn&edition=full","pubTime":"2024-04-22 13:56","pubTimestamp":1713765362,"startTime":"0","endTime":"0","summary":"界面新闻获悉,前先声再明首席运营官、先声药业高级副总裁朱彤今日加入再鼎医药担任大中华区首席商务官,公司现任中华区首席商务官梁怡将于4月30日离开再鼎医药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221356027a54684e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221356027a54684e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428571542","title":"南向资金4月18日净卖出再鼎医药75.56万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428571542","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428571542?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:31","pubTimestamp":1713490292,"startTime":"0","endTime":"0","summary":"4月18日,南向资金减持再鼎医药75.56万股连续3日减持。截止当日收盘,港股通共持有再鼎医药8574.25万股,占流通股8.63%。再鼎医药近5个交易日下跌11.06%,港股通累计减持11.21万股;近20个交易日下跌27.16%,港股通累计增持512.46万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190944308b384c16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190944308b384c16&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428583187","title":"再鼎医药(09688)股价下跌5.179%,现价港币$10.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2428583187","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428583187?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:45","pubTimestamp":1713404700,"startTime":"0","endTime":"0","summary":"[下跌股]再鼎医药(09688) 股价在上午09:45比前收市价下跌5.179%,现股价为港币$10.62。至目前为止,今日最高价为$10.92,而最低价为$10.62。总成交量为35.67万股,总成交金额为港币$383.871万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240418247/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428434295","title":"再鼎医药盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428434295","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428434295?lang=zh_cn&edition=full","pubTime":"2024-04-17 22:35","pubTimestamp":1713364503,"startTime":"0","endTime":"0","summary":"北京时间2024年04月17日22时35分,再鼎医药股票出现异动,股价大幅下跌5.03%。截至发稿,该股报13.70美元/股,成交量10.2034万股,换手率0.10%,振幅5.34%。再鼎医药股票所在的生物技术行业中,整体涨幅为0.86%。其相关个股中,Nls Pharmaceutics Ltd C/Wts 02/02/2026、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Vanda Pharmaceuticals Inc.涨幅较大,Palisade Bio, Inc.、Longeveron Inc.、Jaguar Health, Inc.较为活跃,换手率分别为128.40%、35.65%、32.21%,振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Revolution Medicines Inc C/Wts 17/12/2026 、Dare Bioscience, Inc.,振幅分别为80.94%、40.00%、38.52%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041722350387e8165f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041722350387e8165f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427049684","title":"再鼎医药(09688)股价下跌5.026%,现价港币$10.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2427049684","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2427049684?lang=zh_cn&edition=full","pubTime":"2024-04-15 14:15","pubTimestamp":1713161700,"startTime":"0","endTime":"0","summary":"[下跌股]再鼎医药(09688) 股价在下午02:15比前收市价下跌5.026%,现股价为港币$10.96。至目前为止,今日最高价为$11.46,而最低价为$10.96。总成交量为288.425万股,总成交金额为港币$3.207千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404152321/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2427875403","title":"再鼎医药下跌5.03%,报14.26美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427875403","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427875403?lang=zh_cn&edition=full","pubTime":"2024-04-13 03:24","pubTimestamp":1712949851,"startTime":"0","endTime":"0","summary":"4月13日,再鼎医药(ZLAB)盘中下跌5.03%,截至03:24,报14.26美元/股,成交366.71万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月14日,再鼎医药将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/13032440224654.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427549467","title":"再鼎医药盘中异动 股价大跌5.00%报14.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427549467","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427549467?lang=zh_cn&edition=full","pubTime":"2024-04-13 03:23","pubTimestamp":1712949809,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日03时23分,再鼎医药股票出现波动,股价大幅跳水5.00%。截至发稿,该股报14.26美元/股,成交量24.8997万股,换手率0.25%,振幅4.53%。再鼎医药股票所在的生物技术行业中,整体跌幅为1.76%。其相关个股中,Paxmedica, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Q32 Bio Inc.涨幅较大,Allarity Therapeutics, Inc.、Paxmedica, Inc.、Aptevo Therapeutics Inc.较为活跃,换手率分别为3755.15%、1493.34%、108.72%,振幅较大的相关个股有Paxmedica, Inc.、Allarity Therapeutics, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 ,振幅分别为93.97%、74.01%、63.12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130323297a527bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130323297a527bc1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426441066","title":"再鼎医药下跌5.43%,报15.15美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426441066","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426441066?lang=zh_cn&edition=full","pubTime":"2024-04-11 00:38","pubTimestamp":1712767096,"startTime":"0","endTime":"0","summary":"4月11日,再鼎医药(ZLAB)盘中下跌5.43%,截至00:38,报15.15美元/股,成交316.13万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月14日,再鼎医药将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/11003840189135.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426220410","title":"再鼎医药盘中异动 股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426220410","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426220410?lang=zh_cn&edition=full","pubTime":"2024-04-11 00:38","pubTimestamp":1712767086,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日00时38分,再鼎医药股票出现波动,股价快速下挫5.11%。截至发稿,该股报15.20美元/股,成交量19.2889万股,换手率0.19%,振幅4.62%。再鼎医药股票所在的生物技术行业中,整体跌幅为1.16%。其相关个股中,Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Orgenesis Inc.涨幅较大,Adial Pharmaceuticals, Inc、Silo Pharma, Inc.、Jaguar Health, Inc.较为活跃,换手率分别为1920.27%、76.55%、51.93%,振幅较大的相关个股有Adial Pharmaceuticals, Inc、Orgenesis Inc.、Nutriband Inc C/Wts ,振幅分别为87.61%、74.23%、52.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411003806861e4b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411003806861e4b45&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426481838","title":"美银证券降再鼎医药目标价至16.04元,评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2426481838","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426481838?lang=zh_cn&edition=full","pubTime":"2024-04-10 11:49","pubTimestamp":1712720940,"startTime":"0","endTime":"0","summary":"美银证券发表报告指出,再鼎医药的尼拉帕利、瑞派替尼、甲苯磺酸奥马环素及艾加莫德于2月份的销售分别为5,750万、350万、1,100万及290万元人民币,按年各增长20.8%、2.98倍、6.2倍及不适用,按月则跌18.8%、9.4%、30.6%及0.6%。因此,该行下调对尼拉帕利长期收入预测,对再鼎医药目标价由19.92元下调至16.04元,重申“买入”评级,认为公司商业化进展顺利。沽空资料截至 2024-04-09 16:25。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200925164734831_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200925164734831_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341252/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2425356458","title":"再鼎医药上涨2.03%,报15.76美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425356458","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425356458?lang=zh_cn&edition=full","pubTime":"2024-04-05 22:47","pubTimestamp":1712328448,"startTime":"0","endTime":"0","summary":"4月5日,再鼎医药(ZLAB)盘中上涨2.03%,截至22:47,报15.76美元/股,成交114.09万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月14日,再鼎医药将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/05224740132286.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.1308},{"period":"1month","weight":-0.0173},{"period":"3month","weight":-0.3004},{"period":"6month","weight":-0.323},{"period":"1year","weight":-0.5481},{"period":"ytd","weight":-0.4179}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.113311},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.022208},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.101183},{"month":4,"riseRate":0.428571,"avgChangeRate":0.027858},{"month":5,"riseRate":0.5,"avgChangeRate":0.025011},{"month":6,"riseRate":0.5,"avgChangeRate":0.078087},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.023267},{"month":8,"riseRate":0.666667,"avgChangeRate":0.013621},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.113197},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.064295},{"month":11,"riseRate":0.714286,"avgChangeRate":0.168146},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.005362}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}